Clinical Tip: Is that SCALP lesion tinea capitis?

Article

Tinea capitis is a common pediatric problem. Because treatment requires eight to 12 weeks of oral antifungal medication, accurate diagnosis is essential. A fungal culture that yields Trichophyton tonsurans establishes the diagnosis with certainty.

Hubbard has described certain components of the clinical picture together with the positive predictive value of each (in parenthesis): scaling (1.1), alopecia (3.3), lymphadenopathy, usually in the occipital area (7.5), and pruritus (1.4). The study found that if only one of these components was present, no patient had a positive culture. The presence of two components increased culture positivity to 11%, three components to 92%, and all four components to 100% (Hubbard TW: The predictive value of symptoms in diagnosing childhood tinea capitis. Arch Pediatr Adolesc Med 1999;153[11]:1150).

In our pediatric walk-in clinic, we use the mnemonic SCALP (SCaling, Alopecia, Lymphadenopathy, Pruritus) to make sure all four clinical components are included when a child is evaluated for tinea capitis. Thus, if an intern says, "The patient is a 6-year-old boy with a SCaly circular lesion, 3 cm in diameter, Alopecia, Lymphadenopathy in the cervical area, and Pruritus," he (she) is expressing 100% certainty that the patient needs an antifungal agent.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.